Myocardial infarction, the most severe manifestation of coronary artery disease, is a leading cause of mortality worldwide. Here, a novel nanotherapy engineering approach is reported for enhancing therapeutic effects of mesenchymal stem cells (MSCs) on myocardial ischemiaâreperfusion (MI/R) injury. An antiâoxidative and antiâinflammatory nanotherapy (TPCD NP) is first fabricated. MSCs are successfully engineered with TPCD NP by endocytosis, and TPCD NP engineering does not affect stemness of MSCs. TPCD NPâinternalized MSCs (tnâMSCs) are resistant to oxidative stress, cytotoxicity, and apoptosis induced by reactive oxygen species (ROS). Under oxidative distress, tnâMSCs show stronger paracrine activity compared to MSCs. Consistently, tnâMSCs effectively enhance angiogenesis of endothelial cells under pathological conditions. Also, tnâMSCs protect cardiomyocytes from ROSâinduced cytotoxicity and apoptosis by improving mitochondrial membrane potential and regulating the p53 signaling pathway. In mice with MI/R injury, the survival time of tnâMSCs in the injured heart is prolonged, compared to pristine MSCs. Correspondingly, tnâMSCs more significantly reduce the infarct size, improve cardiac function, and promote cardiac remodeling in MI/R injury mice. Mechanistically, tnâMSCs alleviate MI/R injury by attenuating oxidative stress and inflammation, inhibiting cardiomyocyte apoptosis, and promoting cardiac repair. Consequently, tnâMSCs are promising for treating cardiovascular diseases linked to oxidative distress and inflammation.